FluoroPharma Medical, Inc. (OTCPK: FPMI) entered into a nonbinding letter of intent to acquire Ground Fluor Pharmaceuticals, Inc. on June 9, 2016. The consideration will be paid with restricted stock, not to exceed a majority of FluoroPharma Medical Inc.'s outstanding shares. Thomas Tulip would continue in the role of President and Chief Executive Officer of the combined company. The completion of the transaction is subject to closing of sufficient financing to fund the operations of the combined company, and due diligence review.